Takeda delivered US$203 million in net sales of FRUZAQLA ® in the nine months ended September 2024. This US$20 million payment will be the first ever commercial milestone payment received by ...

First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentiated Portfolio Reflect Company’s Commitment to Providing a Patient-Centric Ecosystem of Support Takeda ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Japan’s largest pharma company Taked today announced that all primary and secondary endpoints were met in two Phase III ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals ...

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, ...

Takeda, which shelled out $8.8 billion for the Massachusetts company back in 2008, is retiring what at one time was an iconic biotech brand. Goodbye Millennium brand, hello big commercial ...

Takeda has established a new global organization aimed at better aligning the company’s R&D and commercial teams, the firm said. The group will be known as the Global Commercial Organization and will ...

Takeda to Acquire Inviragen, Inc. Obtains ... and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones ...

Mersana and Takeda Enter Commercial License Agreement for Novel Fleximer® Antibody-Drug Conjugate. October 27, 2014 08:00 AM Eastern Daylight Time. CAMBRIDGE, Mass.-- ...